Folate targeted solid lipid nanoparticles of simvastatin for enhanced cytotoxic effects of doxorubicin in chronic myeloid leukemia

Current Nanoscience

Volumn 8, Issue 2, 2012, Pages 249-258

  Varshosaz, J ^a   Hassanzadeh, F ^a   Sadeghi, H ^a   Shakery, M ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Chronic meyloid leukemia; Cytotoxicity; Folate targeting; K562 cell line; Simvastatin; Solid lipid nanoparticles

Indexed keywords

CHRONIC MEYLOID LEUKEMIA; FOLATE TARGETING; K562 CELLS; SIMVASTATIN; SOLID LIPID NANOPARTICLE (SLN);

CELL CULTURE; DISEASES; EMULSIFICATION; FLOW CYTOMETRY; NANOPARTICLES; ORGANIC ACIDS; STEARIC ACID;

CYTOTOXICITY;

DODECYLAMINE; DOXORUBICIN; FOLIC ACID; GLYCEROL STEARATE; SIMVASTATIN; SOLID LIPID NANOPARTICLE; TRYPAN BLUE;

ARTICLE; CELL STRAIN K 562; CELL VIABILITY; CHEMICAL REACTION; CHRONIC MYELOID LEUKEMIA; CYTOTOXICITY; DRUG CONJUGATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG RELEASE; DRUG STRUCTURE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL;

EID: 84860307988     PISSN: 15734137     EISSN: 18756786     Source Type: Journal    
DOI: 10.2174/157341312800167542     Document Type: Article

References (46)

1. Stancu, C.; Sima, A. Statins: mechanism of action and effects. J. Cell Mol. Med., 2001, 5(4), 378-387.
2. Cafforio, P.; Dammacco, F.; Gernone, A.; Silvestris, F. Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. Carcinogenesis, 2005, 26(5), 883-891.
3. Rubins, J.B.; Greatens, T.; Kratzke, R.A.; Tan, A.T.; Polunovsky, V.A.; Bitterman, P. Lovastatin induces apoptosis in malignant mesothelioma cells. Am. J. Respir. Crit. Care Med., 1998, 157, 1616-1622.
4. Jones, K.D., Couldwell, W.T.; Hinton, D.R.; Su, Y.; He, S.; Anker, L.; Law, R.E. Lovastatin induces growth inhibition and apoptosis in human malignant glioma cells. Biochem. Biophys. Res. Commun., 1994, 205, 1681-1687.
5. Vitale, M.; Matola, T.; Rossi, G.; Laezza, C.; Fenzi, G.; Bifulco, M. Prenyltransferase inhibitors induce apoptosis in proliferating thyroid cells through a p53-independent, CrmA-sensitive, and caspase-3-like protease-dependent mechanism. Endocrinology, 1999, 140, 698-704.
6. Wong, W.W.L.; Tan, M.M.; Xia, Z.; Dimitroulakos, J.; Minden, M.D.; Penn, L.Z. Cerivastatin triggers tumor-specific apoptosis with higher efficacy than lovastatin. Clin. Cancer Res., 2001, 7, 2067-2075.
7. van de Donk, N.W.C.J.; Kamphuis, M.M.; Lokhorst, H.M.; Bloem, A.C. The cholesterol lowering drug lovastatin induces cell death in myeloma plasma cells. Leukemia, 2002, 16, 1362-1371.
8. Bonadonna, G.; Monfardini, S. Cardiac toxicity of daunorubicin. Lancet, 1969, 1, 837.
9. Gottesman, M.M.; Fojo, T.; Bates, S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer, 2002, 2, 48-58.
10. Riganti, C.; Orecchia, S.; Pescarmona, G.; Betta, P.G.; Ghigo, D.; Bosia, A. Statins revert doxorubicin resistance via nitric oxide in malignant mesothelioma. Int. J. Cancer, 2006, 119, 17-27.
11. Riganti, C.; Doublier, S.; Costamagna, C.; Aldieri, E.; Pescarmona, G.; Ghigo, D.; Bosia, A. Activation of nuclear factor-kappa B pathway by simvastatin and RhoA silencing increases doxorubicin cytotoxicity in human colon cancer HT29 cells. Mol. Pharmacol., 2008, 74(2), 476-484.
12. Sieczkowski, E.; Lehner, C.; Ambros, P.F.; Hohenegger, M. Double impact on p-glycoprotein by statins enhances doxorubicin cytotoxicity in human neuroblastoma cells. Int. J. Cancer, 2010, 126(9), 2025-2035.
13. Chen, R.; Xiao, W.; Li, D.; Mu, S. Combination of simvastatin and imatinib sensitizes the CD34+ cells in K562 to cell death. Med. Oncol., 2010, On line.
14. Yang, Y.C., Huang, W.F.; Chuan, L.M.; Xiao, D.W.; Zeng, Y.L.; Zhou, D.A.; Xu, G.Q.; Liu, W.; Huang, B.; Hu, Q. In vitro and in vivo study of cell growth inhibition of simvastatin on chronic myelogenous leukemia cells. Chemother., 2008, 54(6), 438-446.
15. Will, A. Update on leukaemia. Paed. Child Health, 2008, 18, 107-111.
16. Ross, J.F.; Wang, H.; Behm, F.G.; Mathew, P.; Wu, M.; Booth, R.; Ratnam, M. Folate receptor type beta is a neutrophilic lineage marker and is differentially expressed in myeloid leukemia. Cancer, 1999, 85, 348-357.
17. Biswal, B.K.; Verma, R.S. Differential usage of the transport systems for folic acid and methotrexate in normal human T-lymphocytes and leukemic cells. J. Biochem., 2009, 146, 693-703.
18. Gabizon, A.; Horowitz, A.T.; Goren, D.; Tzemach, D.; Shmeeda, H.; Zalipsky, S. In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice. Clin. Cancer Res., 2003, 9, 6551-6559.
19. Xiang, G.; Wu, J.; Lu, Y.; Liu, Z.; Lee, R.J. Synthesis and evaluation of a novel ligand for folate-mediated targeting liposomes. Int. J. Pharm., 2008, 356, 29-36.
20. Elwood, P.C. Molecular cloning and characterization of the human folatebinding protein cDNA from placenta and malignant tissue culture (KB) cells. J. Biol. Chem., 1989, 264(25), 14893-14901.
21. McHugh, M.; Cheng, Y.C. Demonstration of a high affinity folate binder in human cell membranes and its characterization in cultured human KB cells. J. Biol. Chem., 1979, 254(22), 11312-11318.
22. Lu, Y.; Low, P.S. Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv. Drug Deliv. Rev., 2002, 54, 675-693.
23. Muller, H.; Mader, K.; Gohla, S. Solid lipid nanoparticles for controlled drug delivery-a review of the state of the art. Eur. J. Pharm. Biopharm., 2000, 50, 161-177.
24. Doktorovova, S.; Gokce, E.; Ozyazici, M.; Souto, E.B. Lipid Matrix Nanoparticles: Pharmacokinetics and Biopharmaceutics. Curr. Nanosci., 2009, 5(3), 358-371.
25. Varshosaz, J.; Eskandari, S.; Tabakhian, M. Production and optimization of valproic acid nanostructured lipid carriers by the Taguchi design. Pharm. Dev. Technol., 2010, 15(1), 89-96.
26. Mehner, W.; Mader, K. Solid lipid nanoparticles: Production, characterization and applications. Adv. Drug Deliv. Rev., 2001, 47, 165-196.
27. Zhang, N.; Ping, Q.; Huang, G.; Xu, W. Lecitin-modified solid lipid nanoparticles as carriers for oral administration of insulin. Int. J. Pharm., 2006, 327, 153-159.
28. Shah, M.; Pathak, K. Development and statistical optimization of solid lipid nanoparticles of simvastatin by using 2(3) full-factorial design. AAPS PharmSciTech, 2010, 11(2), 489-496.
29. Ali, H.; Shirode, A.B.; Sylvester, P.W.; Nazzal, S. Preparation, characterization, and anticancer effects of simvastatin-tocotrienol lipid nanoparticles. Int. J. Pharm., 2010, 389(1-2), 223-231.
30. Yuan, H.; Miao, J.; Du, Y.Z.; You, J.; Hu, F.Q.; Zeng, S. Cellular uptake of solid lipid nanoparticles and cytotoxicity of encapsulated paclitaxel in A549 cancer cells. Int. J. Pharm., 2008, 348(1-2), 137-145.
31. Sudimack, J.; Lee, R.J. Targeted drug delivery via the folate receptor. Adv. Drug Deliv. Rev., 2000, 41, 147-162.
32. Varshosaz, J.; Ghaffari, S.; Khoshayand, M.R.; Atyabi, F.; Azarmi, S.; Kobarfard, F. Development and optimization of amikacin solid lipid nanoparticles by central composite design. J. Liposome Res., 2010, 20, 97-104.
33. Salazar, M.D.; Ratnam, M. The folate receptor: what does it promise in tissue-targeted therapeutics? Cancer Metastasis Rev., 2007, 26, 141-152.
34. Wiepz, G.J.; Edwin, F.; Patel, T.; Bertics, P.J. Methods for determining the proliferation of cells in response to EGFR ligands. Methods Mol. Biol., 2006, 327, 179-187.
35. 2+ salts. Cytotechnology, 2000, 32, 93-95.
36. Yasuda, N.; Matzno, S.; Iwano, C.; Nishikata, M.; Matsuyama, K. Evaluation of apoptosis and necrosis induced by statins using fluorescence-enhanced flow cytometry. J. Pharm. Biomed. Anal., 2005, 39, 712-717.
37. Jones, K.D.; Couldwell, W.T.; Hinton, D.R.; Su, Y.; He, S.; Anker, L.; Law, R.E. Lovastatin induces growth inhibition and apoptosis in human malignant glioma cells. Biochem. Biophys. Res. Commun., 1994, 205, 1681-1687.
38. Margulis-Goshen, K.; Magdassi, S. Formation of simvastatin nanoparticles from microemulsion. Nano Med., 2009, 5, 274-281.
39. Chattopadhyay, N.; Zastre, J.; Wong, H.L.; Wu, X.Y.; Bendayan, R. Solid lipid nanoparticles enhance the delivery of the HIV protease inhibitor, atazanavir, by a human brain endothelial cell line. Pharm. Res., 2008, 25, 2262-2271.
40. Bondi, M.L.; Azzolina, A.; Craparo, E.F.; Capuano, G.; Lampiasi, N.; Giammona, G.; Cervello, M. Solid Lipid Nanoparticles Containing Nimesulide: Preparation, Characterization and Cytotoxicity Studies. Curr. Nanosci., 2009, 5(1), 39-44.
41. Suresh, G.; Manjunath, K.; Venkateswarlu, V.; Satyanarayana, V. Preparation, characterization, and in vitro and in vivo evaluation of lovastatin solid lipid nanoparticles. AAPS PharmSciTech, 2007, 8(1), Article 24.
42. Schubert, M.A.; Muller-Goymann, C.C. Characterisation of surface-modified solid lipid nanoparticles (SLN): influence of lecithin and nonionic emulsifier. Eur. J. Pharm. Biopharm., 2005, 61, 77-86.
43. Vivek, K.; Reddy, H.; Murthy, R.S. Investigations of the effect of the lipid matrix on drug entrapment, in vitro release, and physical stability of olanzapine-loaded solid lipid nanoparticles. AAPS PharmSciTech, 2007, 8(4), Article 83.
44. Jain, S.; Mittal, A.; Jain, A.K.; Mahajan, R.R.; Singh, D. Cyclosporin A loaded PLGA nanoparticle: preparation, optimization, in-vitro characterization and stability studies. Curr. Nanosci., 2010, 6(4), 422-431.
45. Chandrasekar, D.; Sistla, R.; Ahmad, F.J.; Khar, R.K.; Diwan, P.V. The development of folate-PAMAM dendrimer conjugates for targeted delivery of anti-arthritic drugs and their pharmacokinetics and biodistribution in arthritic rats. Biomaterials, 2007, 28(3), 504-512.
46. Kim, S.; Lee, J. Folate-targeted drug-delivery systems prepared by nanocomminution. Drug Dev. Ind. Pharm., 2011, 37(2), 131-138.